Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:NVCR 25 January 2026 - 12 February 2026

NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer

NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer

NovoCure shares jumped 23% to $12.91 in U.S. premarket trading Thursday after the FDA approved its Optune Pax device for locally advanced pancreatic cancer. The company said this is the first new FDA-approved treatment for the disease in nearly 30 years. In a Phase 3 trial, median overall survival was 16.2 months with Optune Pax plus chemotherapy, compared to 14.2 months with chemotherapy alone.
12 February 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····

Stock Market Today

  • Lean Hog Futures Decline Amid Lower Pork Prices on Thursday
    March 20, 2026, 2:50 AM EDT. Lean hog futures dropped 60 cents to $2.25 on Thursday as deferred contracts showed mixed results. The national average base hog negotiated price fell $2.80 to $86.14. USDA reported the CME Lean Hog Index edged up 6 cents to $89.94 on Nov. 12. Pork cutout value decreased $3.19 to $94.07 per hundredweight, pressured by a $20.78 decline in belly prices, despite picnic and loin primals rising slightly. USDA estimated hog slaughter at 488,000 head, 28,000 less than last week but slightly higher than the previous year. December 2024 hog futures closed down $1.775 at $80.10, February 2025 at $83.775, down $2.25, and April 2025 at $88.125, down $2.025.
Go toTop